** Drug developer Monopar Therapeutics' shares up 13% at $5.25 premarket
** Company signs agreement with AstraZeneca unit Alexion for the license to AZN's experimental drug being tested for Wilson disease, a rare genetic condition that causes the buildup of toxic copper levels
** Monopar will be responsible for future global development and drug commercialization activities
** Under deal terms, Monopar will pay Alexion an upfront in cash and equity in Monopar
** As of last close, Monopar stock has more than tripled YTD
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((Sruthinarasimha.chari@thosmonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。